A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society

Lothar Bergmann, Viktor Grünwald, Luise Maute, Marc-Oliver Grimm, Steffen Weikert, Jan Schleicher, Theodor Klotz, Jochen Greiner, Anne Flörcken, Arndt Hartmann, Thomas Gauler

Open source

DOI: 10.1159/000508450
Published: 2020
Container: Oncology Research and Treatment
Publisher: S. Karger AG
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1159/000508450,
  title = {A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society},
  author = {Lothar Bergmann and Viktor Grünwald and Luise Maute and Marc-Oliver Grimm and Steffen Weikert and Jan Schleicher and Theodor Klotz and Jochen Greiner and Anne Flörcken and Arndt Hartmann and Thomas Gauler},
  year = {2020},
  journal = {Oncology Research and Treatment},
  doi = {10.1159/000508450},
  url = {https://doi.org/10.1159/000508450}
}

RIS

TY  - JOUR
TI  - A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society
AU  - Lothar Bergmann
AU  - Viktor Grünwald
AU  - Luise Maute
AU  - Marc-Oliver Grimm
AU  - Steffen Weikert
AU  - Jan Schleicher
AU  - Theodor Klotz
AU  - Jochen Greiner
AU  - Anne Flörcken
AU  - Arndt Hartmann
AU  - Thomas Gauler
PY  - 2020
JO  - Oncology Research and Treatment
DO  - 10.1159/000508450
UR  - https://doi.org/10.1159/000508450
ER  -

APA

Bergmann, L., Grünwald, V., Maute, L., Grimm, M., Weikert, S., Schleicher, J., Klotz, T., Greiner, J., Flörcken, A., Hartmann, A., & Gauler, T. (2020). A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. Oncology Research and Treatment. https://doi.org/10.1159/000508450

Source records

crossref · retrieved 2026-09-26T01:17:31.352Z